Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 528-533

  Varghese, Julie M ^a   Jarrett, Paul ^b   Wallis, Steven C ^a   Boots, Robert J ^a,b   Kirkpatrick, Carl M J ^c   Lipman, Jeffrey ^a,b   Roberts, Jason A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Microdialysis; Pharmacodynamics; Pharmacokinetics; Target sites; lactams

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; INTERSTITIAL FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; OBSERVATIONAL STUDY; ORGANIZING PNEUMONIA; PLASMA CONCENTRATION-TIME CURVE; PROSPECTIVE STUDY; SEPTIC SHOCK; VENTILATOR ASSOCIATED PNEUMONIA; VOLUME OF DISTRIBUTION; CRITICAL ILLNESS; EXTRACELLULAR FLUID; HEMODIAFILTRATION; INTENSIVE CARE UNIT; MIDDLE AGED; PLASMA; RENAL REPLACEMENT THERAPY;

AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CRITICAL ILLNESS; EXTRACELLULAR FLUID; FEMALE; HEMODIAFILTRATION; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; THIENAMYCINS;

EID: 84922439153     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku413     Document Type: Article

References (28)

1. Uchino S, Kellum JA, Bellomo R et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-8.
2. Hoste EAJ, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med 2008; 36: S146-S51.
3. Bellomo R, Cass A, Cole L et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627-38.
4. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
5. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31: 2742-51.
6. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Micro 2004; 2: 289-300.
7. Joukhadar C, Frossard M, Mayer BX et al. Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-91.
8. Roberts JA, Roberts MS, Robertson TA et al. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009; 37: 926-33.
9. Roberts JA, Kirkpatrick CMJ, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
10. Muller M. Science, medicine, and the future: microdialysis. BMJ 2002; 324: 588-91.
11. Joukhadar C, Klein N, Mayer BX et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002; 30: 1478-82.
12. Sauermann R, Delle-Karth G, Marsik C et al. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother 2005; 49: 650-5.
13. de la Pena A, Liu P, Derendorf H. Microdialysis in peripheral tissues. Adv Drug Deliv Rev 2000; 45: 189-216.
14. Bouw MR, Hammarlund-Udenaes M. Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of a retrodialysis method. Pharm Res 1998; 15: 1673-9.
15. Bilgrami I, Roberts JA, Wallis SC et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother 2010; 54: 2974-8.
16. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27: 10-22.
17. Dahyot C, Marchand S, Bodin M et al. Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Clin Pharmacokinet 2008; 47: 181-9.
18. Tegeder I, Schmidtko A, Brautigam L et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002; 71: 325-33.
19. Dahyot-Fizelier C, Timofeev I, Marchand S et al. Brain microdialysis study of meropenem in two patients with acute brain injury. Antimicrob Agents Chemother 2010; 54: 3502-4.
20. Karjagin J, Lefeuvre S, Oselin K et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008; 83: 452-9.
21. Tomaselli F, Maier A, Matzi V et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004; 48: 2228-32.
22. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51.
23. Udy AA, Roberts JA, De Waele JJ et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39: 455-7.
24. Zeitlinger BS, Zeitlinger M, Leitner I et al. Clinical scoring system for the prediction of target site penetration of antimicrobials in patients with sepsis. Clin Pharmacokinet 2007; 46: 75-83.
25. Bax RP, Bastain W, Featherstone A et al. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989; 24: 311-20.
26. de Stoppelaar F, Stolk L, van Tiel F et al. Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother 2000; 46: 150-1.
27. Krueger WA, Schroeder TH, Hutchison M et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998; 42: 2421-4.
28. Robatel C, Decosterd LA, Biollaz J et al. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol 2003; 43: 1329-40.